Bipolar Disorder Therapeutics Market Size, Share Global Analysis Report, 2020–2026

Industry Insights

The bipolar disorder therapeutics market report analyzes and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire bipolar disorder therapeutics market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

This specialized and expertise-oriented industry research report scrutinizes the technical and commercial business outlook of the bipolar disorder therapeutics industry. The report analyzes and declares the historical and current trends analysis of the bipolar disorder therapeutics industry and subsequently recommends the projected trends anticipated to be observed in the bipolar disorder therapeutics market during the upcoming years.

Key Insights from Primary Research

• According to the primary CXO’s of the global bipolar disorder therapeutics market, the market is estimated to witness a substantial growth of nearly 2.0% over the forecast period.
• The market was valued at USD 3,816.2 million, in 2019 and is expected to be valued at over USD 4,384.2 million.
• On the basis of the product segment, antipsychotic drugs dominated the global bipolar disorder therapeutics market in 2019. In terms of revenue, it accounted for more than a 30% share of the total market in 2019.
• Asia Pacific market is expected to be the fastest goring region for bipolar disorder therapeutics over the forecast period owing to growing investments for R&D and pharmaceutical companies in the region.
• By geography, the North American region headed the market with a share of above 30%, in 2019.

Key Recommendations from Analysts

• The higher prevalence of bipolar disorders, technological advances, high unmet medical needs, and government initiatives are major factors that are expected to drive the development of the treatment market for bipolar disorders in the near future.
• The strategic developments such as regional expansion, product innovations, and on-going research and developments by the major companies such as Graphiq, Inc, Pare likely Pfizer Inc., Novartis AG, etc. are likely to boom the market’s growth over the upcoming years.
• Our analysts recommend that the Asia Pacific region is predicted to witness significant growth attributed to the growing demand for bipolar disorder therapeutics from China and India.  
• Expansion of pharmaceutical companies especially in emerging markets is anticipated to fuel the demand for bipolar disorder therapeutics drugs in developing regions over the forthcoming years.
• Strengthening the distribution channel and growing availability of bipolar disorder drugs online may also help the major player to cater to the lucrative growth of the market over the years to come.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the bipolar disorder therapeutics industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the bipolar disorder therapeutics industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the bipolar disorder therapeutics market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the bipolar disorder therapeutics industry. The bipolar disorder therapeutics market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the bipolar disorder therapeutics sector. Key strategic developments in the bipolar disorder therapeutics market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the bipolar disorder therapeutics market are appropriately highlighted in the report.

The bipolar disorder therapeutics market research report delivers an acute valuation and taxonomy of the bipolar disorder therapeutics industry by practically splitting the market on the basis of different types, categories, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the bipolar disorder therapeutics industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. Further, country-wise data for the bipolar disorder therapeutics industry is provided for the leading economies of the world.

Bipolar episodes are characterized by a sudden change in behavior and emotional state, ranging from excessive and joyful to terribly sad and depressive. These disorders include different types of episodes including hypomanic episodes, manic episodes, mixed episodes, and depression episodes. Triggers for bipolar disorder include stressful life events, childhood trauma, genetic inheritance, and self-esteem issues.

People around the world viewed "March 30" as World Bipolar Day to create awareness of the condition and remove the stigma of the mental disorder. Huge numbers of people with this condition of mind are dependent on alcohol to raise their emotional state. According to the National Institute on Alcohol Abuse and Alcoholism, about 27 percent of people with bipolar disorder are drug dependent, and about 15 percent are involved in alcohol abuse.

The bipolar disorder therapeutics market is segmented based on drug type and region.  On the basis of drug type segmentation, the market is classified into antidepressant drugs, mood stabilizers, antipsychotic drugs, and others.

Report Scope

Some of the essential players operating in the bipolar disorder therapeutics market, but not restricted include: 

•  Glaxo SmithKline (GSK)
•   Eli Lilly
•  AstraZeneca
•  Pfizer Inc.
•  Janssen Pharmaceuticals
•  AbbVie Inc.
•  Novartis AG
•   Bristol-Myers Squibb Company Allergan Plc.
•  Otsuka Holdings Co. Ltd.

The taxonomy of the bipolar disorder therapeutics industry by its scope and segmentation is as follows:

By Drug Type Segmentation Analysis

• Antidepressant Drugs
• Mood Stabilizers
• Antipsychotics Drugs
• Others

Regional Segmentation Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa